Search review questions

Neurocognitive function · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

Any congenital anomalies · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

Blood arsenic Measured by change in GM of blood arsenic concentrations from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

Urinary arsenic Measured by percentage (%) of InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

Plasma homocysteine Measured by change in GM of plasma homocysteine concentrations from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

All‐cause mortality · adult men and women who had been exposed to arsenic‐containing drinking water

Neurocognitive function · adult men and women who had been exposed to arsenic‐containing drinking water

Any congenital anomalies · adult men and women who had been exposed to arsenic‐containing drinking water

Blood arsenic Measured by change in total blood arsenic, InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water

Urinary arsenic Measured by change in percentage (%) of InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water

Plasma homocysteine Measured by change in plasma homocysteine concentrations from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water

Any type of cancer · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

All‐cause mortality · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L…

Change in BMD lumbar spine (%, assessed at 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Adverse events (ongoing reporting, up to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

Efficacy (changes in symptoms of ADHD): investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Clinical impression: severity ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Clinical impression: improvement‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Anxiety: investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Depression: investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Efficacy (changes in symptoms of ADHD): participant‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Clinical impression: severity · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Clinical impression: improvement · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Anxiety: investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Depression: investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Efficacy (changes in symptoms of ADHD): investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

Outcomes · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Treatment efficacy (change in OCD score), end of treatment. Measured by Y‐BOCs Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Total number of dropouts, end of treatment · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Quality of life, end of treatment Measured by WSAS Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Severity of depressive symptoms, end of treatment Measured by BDI Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Severity of anxiety symptoms, end of treatment Measured by BDI Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Behavioural difficulties, end of treatment · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)

Social interaction impairment · children aged 5 to 11 years with ASD

Social communication impairment · children aged 5 to 11 years with ASD

Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD

Total adverse events · children aged 5 to 11 years with ASD

Non‐core symptoms of ASD · children aged 5 to 11 years with ASD

Tolerability · children aged 5 to 11 years with ASD

Stuttering frequency (% SS) · children aged six years and younger who stutter

Stuttering severity · children aged six years and younger who stutter

Speech efficiency (syllables per second) · children aged six years and younger who stutter

Communication attitudes · children aged six years and younger who stutter